Health Care · Pharmaceutical Preparations

RCKT ROCKET PHARMACEUTICALS, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1281895130 filings
Russell 2000

RCKT at a glance

ROCKET PHARMACEUTICALS, INC. (RCKT, SEC CIK 1281895) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and a net loss of $223.1 million. Diluted EPS was -$2.01.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding ROCKET PHARMACEUTICALS, INC. (RCKT) shares worth $110.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Wilson Martin on November 18, 2026 of 677 shares at $2.18 per share.
  • In the last 90 days, RCKT insiders reported 0 open-market purchases ($0) and 7 open-market sales ($418K) on Form 4, a net sale of $418K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$0
10-K XBRL
Insiders · 90 days
0 buys · 7 sells
Net −$418K
13F holders
28 funds
$110.6M · −2 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New secured debt risk: September 30, 2026 Loan Agreement provides up to $150.0 million, secured by substantially all assets
  • Regulatory and covenant risk: RP-A501 clinical hold or discontinuation raises qualified-cash requirement to 75% of outstanding principal
  • Operational flexibility risk: Loan covenants restrict financing, acquisitions, asset licensing, and strategic transactions
  • Interest-rate risk: Term Loans bear floating interest at the greater of 9.15% or prime rate plus 2.40%
  • Liquidity risk: $50.0 million final tranche requires lenders’ investment committee approval in its sole discretion

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product sales; KRESLADI™ not expected to generate near-term material revenue
  • Operating loss $51.0M vs $52.2M YoY; operating margin not applicable with zero revenue
  • Danon R&D $6.2M vs $5.6M YoY, strongest program investment; RP-A601 R&D $1.0M vs $1.5M
  • Cash, equivalents and investments $279.4M at September 30; operating cash use $124.1M nine-month
  • Hercules financing provided $35M initial draw; runway projected into third quarter 2028, with additional borrowing potentially extending to 2029

AI summary of the RCKT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial information announced for quarter ended September 30, 2026
  • Investor focus: Exhibit 99.1 contains the company’s detailed results and management commentary

Item EX-99.1: Item EX-99.1

  • FDA alignment supports a 12-patient RP-A501 pivotal Phase 2, with dosing targeted by mid-2027 and topline results in mid-2028
  • Danon efficacy bar: at least 7 of 12 patients meeting both LAMP2 expression and 10% LV mass-index reduction endpoints
Filed Oct 6, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Credit facility up to $150 million with Hercules Capital, adding funding flexibility for RP-A501’s pivotal Phase 2 Danon study
  • $35 million funded at closing, with potential additional draws of $35 million, $30 million upon a Danon milestone, and $50 million subject to approval

Item EX-99.2: Item EX-99.2

  • RP-A501 Phase 1 showed durable cardiac benefit up to 7 years, with 100% overall survival and transplant-free survival median not reached
  • Pivotal Phase 2 Cohort 4 uses recalibrated dose and revised immunomodulation after serious adverse events in discontinued Cohort 3

Item 1.01: Entry into a Material Definitive Agreement

  • $35.0M funded, with total senior secured borrowing capacity up to $150.0M across five tranches
  • Floating interest rate: greater of prime rate or 6.75%, plus 2.40%, creating substantial rate exposure

Item 7.01: Regulation FD Disclosure

  • Loan Agreement with Hercules announced, indicating new financing for Rocket Pharmaceuticals
  • Investor presentation updates the Danon Disease Program, relevant to clinical and corporate outlook

Item 3.02: Unregistered Sales of Equity Securities

  • Warrants issued to lenders in a private placement under Securities Act Section 4(a)(2)
  • Underlying common shares unregistered, creating potential future dilution if warrants are exercised
Filed Sep 15, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • FDA alignment supports continued enrollment and dosing in RP-A501’s global pivotal Phase 2 Danon disease trial
  • Recalibrated dose and 12-patient pivotal population define the updated trial design

Item EX-99.1: Item EX-99.1

  • FDA alignment preserves RP-A501’s pivotal Phase 2 path and potential accelerated approval strategy in Danon disease
  • Pivotal population set at 12 male patients receiving 3.8 × 10¹³ GC/kg; first three patients count toward efficacy population

AI summaries of RCKT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for RCKT

Don't miss the next RCKT filing

  • Alerts as it files. A push when RCKT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut RCKT, by share count.
  • Ask anything. An AI agent that reads every RCKT filing and answers with sources.

RCKT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Wilson MartinSellNov 18, 2026$2.18
Shah GauravSellNov 18, 2026$2.18
Wilson MartinSellNov 13, 2026$2.25
Shah GauravSellNov 13, 2026$2.25
Chaudhuri SarbaniSellNov 9, 2026$2.33
Wilson MartinSellNov 5, 2026$2.39
Wilson MartinSellSep 11, 2026$3.40
Shah GauravSellAug 18, 2026$3.38

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$0$0
Operating Income--$273.2M-$231.7M
Net Income-$245.6M-$258.7M-$223.1M
Balance Sheet
Total Assets$566.3M$527.7M$330.4M
Equity-$463.2M$277.2M
ROE--55.9%-80.5%
Per Share
EPS$-2.92$-2.73$-2.01
Cash Flow
Operating CF--$209.7M-$190.0M
CapEx$16.4M$5.9M$440K

Source: XBRL data in ROCKET PHARMACEUTICALS, INC. (RCKT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate RCKT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
RCKT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$110.6M
Q2 202630$157.7M
Q1 202629$158.5M
Q4 202526$149.2M
Q3 202527$126.9M
Q2 202526$78.1M
Q1 202523$139.0M
Q4 202419$223.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 208 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

RCKT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 17, 2026--
4Nov 17, 2026--
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Nov 12, 2026--
4Nov 9, 2026--
8-KOct 6, 2026Analysis-
4Sep 15, 2026--
8-KSep 15, 2026Analysis-
8-KAug 27, 2026Analysis-
4Aug 20, 2026--
4Aug 20, 2026--
4Aug 17, 2026--
4Aug 17, 2026--
4Aug 13, 2026--
4Aug 13, 2026--
8-KAug 10, 2026Analysis-
10-QAug 10, 2026Analysis
4Aug 5, 2026--
4Aug 5, 2026--
8-KAug 3, 2026Analysis-
SC 13GJul 31, 2026-
4Jul 6, 2026--

Related Health Care companies

All Health Care →

RCKT SEC filings: frequently asked questions

Are RCKT insiders buying or selling?

In the last 90 days, ROCKET PHARMACEUTICALS, INC. (RCKT) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $417,906 by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold RCKT stock?

As of September 30, 2026, the largest ROCKET PHARMACEUTICALS, INC. (RCKT) holders among the 13F filers tracked by SignalX were BlackRock ($34.6 million), Millennium Management ($12.7 million), Citigroup ($12.1 million), Vanguard Capital Management LLC ($10.1 million), State Street Corp ($4.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was RCKT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ROCKET PHARMACEUTICALS, INC. (RCKT) reported revenue of $0 and a net loss of $223.1 million. Diluted EPS was -$2.01. The figures come from the XBRL data in the 10-K.

What did RCKT report in its latest 8-K?

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial information announced for quarter ended September 30, 2026.

What are the latest RCKT SEC filings?

ROCKET PHARMACEUTICALS, INC. (RCKT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 20, 2026.

What is RCKT's SEC CIK number?

ROCKET PHARMACEUTICALS, INC. (RCKT)'s SEC Central Index Key (CIK) is 1281895. EDGAR lists every RCKT filing under that number.

Ask anything about RCKT

The research agent reads RCKT's filings, financials, insider trades and 13F holders, then answers with sources.